Hologic’s HOLX acquisition of Biotheranostics in 2021 accelerated its entry into a large, fast-growing oncology adjacency. The business also carries higher margins than the company’s legacy service ...
bioTheranostics, Inc's Breast Cancer Index, a genomic test quantifying the risk of breast cancer recurrence and predicting which patients will likely benefit from extended endocrine therapy, will be ...
Norman Parathyroid Center, Clayman Thyroid Center, and Carling Adrenal Center Expand Their Lead as the World’s ...
Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial. Rate of medical ...
New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration Findings from 11 ...
First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed ...
Please provide your email address to receive an email when new articles are posted on . An assessment of free cortisol after a dexamethasone suppression test could add value to the diagnostic workup ...
When these hormones become imbalanced, it can lead to the development of an endocrine disorder. “An endocrine disorder occurs when your body produces either too much or too little of a particular ...
Endocrine disruptors (EDs) are hormone-like substances that can have undesirable effects on health. For example, chemicals can increase the risk of breast cancer if they act in a manner similar to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results